Carl Zeiss Meditec (ETR:AFX) Stock Price Up 1.2% - Time to Buy?

Key Points

• Carl Zeiss Meditec AG shares rose by 1.2%, trading at €51.15 ($58.79), following a previous close of €50.55 ($58.10).
• The company has a market cap of $4.77 billion and a P/E ratio of 27.34, indicating its growth prospects and valuation in the market.
• Carl Zeiss Meditec operates across two segments, Ophthalmology and Microsurgery, focusing on diagnostic and treatment solutions for chronic eye diseases.

Carl Zeiss Meditec AG (ETR:AFX - ) rose 1.2% on Wednesday . The company traded as high as €51.95 ($59.71) and last traded at €51.15 ($58.79). Approximately 88,191 shares were traded during trading, a decline of 7% from the average daily volume of 94,405 shares. The stock had previously closed at €50.55 ($58.10).

Carl Zeiss Meditec Stock Up 1.2%

The stock's 50 day simple moving average is €55.79 and its two-hundred day simple moving average is €57.05. The firm has a market cap of $4.77 billion, a P/E ratio of 27.34, a P/E/G ratio of 2.83 and a beta of 0.98. The company has a debt-to-equity ratio of 7.41, a current ratio of 2.13 and a quick ratio of 2.47.

About Carl Zeiss Meditec

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.